Quintiles Transnational Holdings Inc (Q) was Initiated by Goldman to “Buy” and the brokerage firm has set the Price Target at $94. Goldman advised their investors in a research report released on Oct 5, 2016.
Many Wall Street Analysts have commented on Quintiles Transnational Holdings Inc. Quintiles Transnational Holdings Inc was Upgraded by Avondale to ” Mkt Outperform” on Jul 12, 2016.
On the company’s financial health, Quintiles Transnational Holdings Inc reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.90. The company had revenue of $1167.10 million for the quarter, compared to analysts expectations of $1150.61 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS.
Quintiles Transnational Holdings Inc closed down -1.41 points or -1.76% at $78.79 with 15,64,160 shares getting traded on Tuesday. Post opening the session at $80.2, the shares hit an intraday low of $78.61 and an intraday high of $80.78 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Jun 10, 2016, Kevin K Gordon (EVP and COO) sold 24,000 shares at $66.41 per share price. According to the SEC, on May 16, 2016, Annie H. Lo (director) purchased 502 shares at $64.80 per share price. On Sep 3, 2015, Charles Edward Williams (Sr VP and Controller) sold 5,000 shares at $72.43 per share price, according to the Form-4 filing with the securities and exchange commission.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.